US FDA Asks Sponsors Of Discontinued Naloxones To Consider Return To Market

 
• By Derrick Gingery

In announcing expedited assessments for new naloxone ANDAs, the agency also offers guidance to sponsors of discontinued products considering a return to marketing.

An ampoule Opioid next to it is a note written in English Opioid epidemic. All around, many tablets and syringes are scattered.
US FDA wants to increase the availability of naloxone, which is used for emergency opioid overdoses. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics